{"id":8761,"date":"2026-06-18T16:47:20","date_gmt":"2026-06-18T19:47:20","guid":{"rendered":"https:\/\/mbinitiative.org\/?page_id=8761"},"modified":"2026-07-01T15:27:31","modified_gmt":"2026-07-01T18:27:31","slug":"impact-report-june-2026","status":"publish","type":"page","link":"https:\/\/mbinitiative.org\/pt\/impact-report-june-2026\/","title":{"rendered":"Impact Report | June 2026"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Relat\u00f3rios<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tSetembro 2024<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tFevereiro 2025<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tMaio de 2025<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tSetembro 2025<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tJunho 2026<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\n\t\n<\/svg>\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

The\nMedulloblastoma \nInitiative<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Relat\u00f3rio de Impacto<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Junho 2026<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Lynne El \nGhorayeb, \nPharmD (\u00e0 \nesquerda), e Dalia \nHaydar, PharmD, PhD, \nque lidera um laborat\u00f3rio \nde imunoterapia no Hospital \nChildren\u2019s National, preparam o \nlan\u00e7amento de um novo ensaio \ncl\u00ednico com o apoio da MB<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

DE NOVAS COLABORA\u00c7\u00d5ES A
\nENSAIOS CL\u00cdNICOS INOVADORES<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u275d <\/span>As tecnologias \ncom c\u00e9lulas CAR \nT representam \numa grande \noportunidade \npara melhorar \nos desfechos de \npacientes com \nmeduloblastoma.\u201d<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

- Roger J. Packer, MD, \nrespons\u00e1vel pela \ncoordena\u00e7\u00e3o cient\u00edfica \nda MBI e diretor do Brain \nTumor Institute no Hospital \nChildren\u2019s National, em \nWashington, D.C.<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A Medulloblastoma Initiative (MBI) continua correndo \ncontra o tempo para descobrir curas para o tipo de tumor \ncerebral maligno mais comum em crian\u00e7as. At\u00e9 um em \ncada tr\u00eas pacientes com meduloblastoma n\u00e3o sobrevive \n\u00e0 doen\u00e7a devido \u00e0 falta de op\u00e7\u00f5es terap\u00eauticas eficazes \npara casos de recidiva.<\/p>

Em abril, menos de 1 ano ap\u00f3s o lan\u00e7amento do nosso \nensaio cl\u00ednico de imunoterapia MATCHPOINT (ver p\u00e1gina \n4), demos in\u00edcio a um segundo ensaio cl\u00ednico autorizado \npela Food and Drug Administration (FDA) dos Estados \nUnidos. O estudo envolve uma vacina baseada em RNA \nmensageiro (mRNA) e j\u00e1 come\u00e7ou a recrutar pacientes, \ntrazendo uma nova esperan\u00e7a para as fam\u00edlias (ver \np\u00e1gina 5).<\/p>

A MBI tamb\u00e9m ampliou sua rede de pesquisa para \nacelerar o progresso. Especialistas do Children\u2019s Hospital \nof Philadelphia (CHOP) e do Seattle Children\u2019s Hospital \npassaram a integrar a equipe cient\u00edfica da iniciativa. \nEsses pesquisadores fortalecer\u00e3o os esfor\u00e7os liderados \npelo Hospital Children\u2019s National, em Washington, D.C., \npara desenvolver terapias com c\u00e9lulas T portadoras \nde receptor de ant\u00edgeno quim\u00e9rico (CAR T) para o \ntratamento do meduloblastoma.<\/p>

As c\u00e9lulas CAR T modificam as c\u00e9lulas T do pr\u00f3prio \npaciente \u2014 um tipo de gl\u00f3bulo branco \u2014 para que \nreconhe\u00e7am e destruam c\u00e9lulas cancer\u00edgenas. O \nChildren\u2019s National pretende solicitar \u00e0 FDA, ainda este \nano, autoriza\u00e7\u00e3o para iniciar o primeiro ensaio cl\u00ednico \nem humanos dessa abordagem terap\u00eautica para o \nmeduloblastoma (ver p\u00e1gina 6).<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u275d As doa\u00e7\u00f5es \u00e0 MBI viabilizar\u00e3o a condu\u00e7\u00e3o de novos ensaios \ncl\u00ednicos. Nossa comunidade deu in\u00edcio a um esfor\u00e7o sem \nprecedentes para desenvolver terapias inovadoras que nos \naproximem cada vez mais da cura.<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u2014 Fernando Goldsztein, MBA, fundador da Medulloblastoma Initiative<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Esse ritmo acelerado de conquistas reflete o empenho incans\u00e1vel da MBI em \nencontrar a cura para o meduloblastoma.<\/p>

A coragem dos pacientes e de suas fam\u00edlias fortalece a determina\u00e7\u00e3o de \nnossos cientistas em avan\u00e7ar a pesquisa. \u201cCada momento conta\u201d, afirma o Dr. \nPacker. \u201cN\u00e3o temos tempo para trabalhar de forma sequencial. A MBI foi criada \npara impulsionar m\u00faltiplas frentes de pesquisa ao mesmo tempo. Todos os \npesquisadores compartilham seus dados de forma imediata.\u201d<\/p>

A MBI e o Children\u2019s National agradecem profundamente o seu apoio ao nosso \nmovimento global. Este relat\u00f3rio destaca os avan\u00e7os alcan\u00e7ados at\u00e9 o in\u00edcio de \n2026, com foco especial nos mais recentes desenvolvimentos em imunoterapia.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Uma promessa compartilhada<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Para saber mais sobre a iniciativa \ne nossa promessa a crian\u00e7as em \ntodo o mundo, assista ao mais \nnovo v\u00eddeo da MBI.
Escaneie o QR code ou acesse: mbinitiative.org<\/a><\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

ENSAIOS CL\u00cdNICOS DA MBI\nALCAN\u00c7AM
NOVOS MARCOS<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

No primeiro semestre de 2026, ensaios cl\u00ednicos apoiados pela MBI e aprovados \npela FDA deram passos importantes rumo a potenciais descobertas.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

MATCHPOINT<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Diversos pacientes j\u00e1 receberam tratamento desde o in\u00edcio do ensaio cl\u00ednico \nMATCHPOINT, liderado por Duane Mitchell, MD, PhD, na University of Florida.

O MATCHPOINT combina as c\u00e9lulas T do pr\u00f3prio paciente com um \nmedicamento que auxilia o sistema imunol\u00f3gico a superar os mecanismos de \ndefesa do tumor. Antes de receberem a terapia, os pacientes passam por uma \ns\u00e9rie de vacina\u00e7\u00f5es utilizando suas pr\u00f3prias c\u00e9lulas dendr\u00edticas \n\u2014 um tipo de c\u00e9lula do sistema imunol\u00f3gico que \najuda as c\u00e9lulas T a reconhecerem c\u00e9lulas \ncancer\u00edgenas. \u201cEsperamos observar \natividade antitumoral\u201d, afirma o Dr. Mitchell. \n\u201cAcreditamos que confirmaremos \na viabilidade dessa abordagem \ne esperamos demonstrar sua \nseguran\u00e7a e resposta cl\u00ednica.\u201d
will confirm the feasibility and look forward to establishing safety and
clinical response.\u201d

Aprovado pela FDA em 2024, o \nMATCHPOINT se tornar\u00e1 um \nensaio multic\u00eantrico quando \ncome\u00e7ar a recrutar pacientes \ntamb\u00e9m no Children\u2019s National, \nainda este ano. O estudo \noferece esperan\u00e7a concreta \npara pacientes que atualmente \ncarecem de op\u00e7\u00f5es.
tangible hope for patients who currently lack treatment options.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Duane Mitchell<\/strong>, MD, PhD (acima), lidera \no ensaio cl\u00ednico MATCHPOINT<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u275d N\u00e3o sei se este estudo ser\u00e1 a cura, mas a base que est\u00e1 \nsendo constru\u00edda certamente ser\u00e1. O investimento da \nMBI tornou isso poss\u00edvel.\u201d<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u2014 Elias Sayour, MD, PhD<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Ensaio cl\u00ednico da vacina de mRNA<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

O recrutamento de pacientes para o ensaio cl\u00ednico \nliderado por Elias Sayour, MD, PhD, come\u00e7ou em abril. \nO Dr. Sayour est\u00e1 desenvolvendo uma plataforma \nde imunoterapia baseada em mRNA, projetada para \nfornecer vacinas personalizadas contra o c\u00e2ncer. O \nPediatric Neuro-Oncology Consortium (PNOC), \numa rede de pesquisa internacional, e a FDA j\u00e1 \naprovaram o estudo.<\/p>

Ao longo do \u00faltimo ano, o Dr. Sayour \nobteve avan\u00e7os consistentes na \nprodu\u00e7\u00e3o da vacina na University of \nFlorida.
.\u201cNenhum outro centro acad\u00eamico \nno mundo faz o que estamos fazendo\u201d,<\/strong> afirma o Dr. Sayour ao descrever \no processo de produ\u00e7\u00e3o, em seu \nlaborat\u00f3rio, de vacinas de mRNA \nutilizando nanopart\u00edculas lip\u00eddicas. \nEle tamb\u00e9m estabeleceu um \nprotocolo para transportar essas \nvacinas com seguran\u00e7a para outros \ncentros, permitindo o tratamento de \nmais pacientes.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Elias Sayour<\/strong>r, MD, PhD (ao centro), lidera \num esfor\u00e7o pioneiro de pesquisa com \nvacinas de mRNA voltado \u00e0 busca da cura do \nmeduloblastoma.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

O PR\u00d3XIMO PASSO NA \nTECNOLOGIA DE C\u00c9LULAS CAR T<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Novos estudos que exploram abordagens inovadoras seguem os \npassos dos dois estudos da MBI atualmente em andamento.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Um plano ousado para \u201cDERROTAR\u201d \no meduloblastoma<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Dr. Haydar<\/strong> (left)<\/strong> (\u00e0 direita) comparando \ninforma\u00e7\u00f5es com sua equipe de pesquisa \ndo DEFEAT-MB, no Children\u2019s National.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Dalia Haydar, PharmD, PhD, pesquisadora do Children\u2019s National, est\u00e1 profundamente \ncomprometida com a busca por uma cura para crian\u00e7as com meduloblastoma \nrecidivado. \u201cVou dormir pensando na pesquisa. Acordo pensando nela\u201d<\/strong>, afirma. Gra\u00e7as \n\u00e0 MBI, a Dra. Haydar tem a oportunidade \u00fanica de transformar esse objetivo em \nrealidade. Ela est\u00e1 se preparando para iniciar um novo ensaio cl\u00ednico at\u00e9 o final de \n2026.<\/p>

O ensaio cl\u00ednico DEFEAT-MB tem como alvo espec\u00edfico dois marcadores proteicos \nfrequentemente expressos pelos tumores de meduloblastoma: GPC2 e B7-H3. Ser\u00e1 a \nprimeira avalia\u00e7\u00e3o dessa abordagem em seres humanos. Essa terapia inovadora tem \no potencial de eliminar c\u00e9lulas tumorais enquanto preserva c\u00e9lulas saud\u00e1veis.<\/p>

\u201cEste \u00e9 o pr\u00f3ximo passo na tecnologia de c\u00e9lulas CAR \nT\u201d, explica a Dra. Haydar. \u201cQuando se tem como \nalvo apenas um marcador, algumas c\u00e9lulas \ncancer\u00edgenas podem escapar deixando de \nexpress\u00e1-lo.<\/p>

Ao direcionar a terapia a dois \nmarcadores simultaneamente, aumentam \nas chances de localizar e destruir um \nn\u00famero maior de c\u00e9lulas tumorais. Isso \ntamb\u00e9m pode ajudar a manter as c\u00e9lulas \nimunol\u00f3gicas ativas por mais tempo, \nevitando sua exaust\u00e3o.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u275d Sem o investimento e o apoio da MBI, este \nensaio cl\u00ednico ainda levaria pelo menos 5 anos \npara se tornar realidade.\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u2014 Dalia Haydar, PharmD, PhD<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A equipe da Dra. Haydar testou mais de 20 vers\u00f5es diferentes para identificar a \nop\u00e7\u00e3o mais eficaz e duradoura. \u201cQuer\u00edamos selecionar, de forma sistem\u00e1tica e \ncom confian\u00e7a, algo que fosse capaz de enfrentar diferentes formas agressivas de \nmeduloblastoma\u201d, afirma.<\/p>

O ensaio cl\u00ednico ter\u00e1 como foco inicial crian\u00e7as com as formas de meduloblastoma \nmais dif\u00edceis de tratar (Grupo 3 e Grupo 4), especialmente aquelas que deixaram de \nresponder \u00e0s terapias convencionais.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Reinfus\u00e3o<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Infogr\u00e1fico adaptado de: National Institute of Cancer
(https:\/\/www.cancer.gov\/about-cancer\/ treatment\/research\/car-t-cell-therapy-infographic<\/a>)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Os CARVengers<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A MBI est\u00e1 revolucionando a pesquisa em tumores cerebrais ao reunir especialistas \nde refer\u00eancia mundial em uma \u00fanica equipe, com um objetivo comum: encontrar a \ncura o mais r\u00e1pido poss\u00edvel.<\/p>

A equipe de c\u00e9lulas CAR T da MBI adotou o apelido CARVengers, uma \nrefer\u00eancia aos super-her\u00f3is Avengers (Vingadores) dos quadrinhos e filmes da \nMarvel. Em 2025, tr\u00eas l\u00edderes cient\u00edficos juntaram-se \u00e0 MBI para trabalhar ao \nlado da Dra. Haydar na prepara\u00e7\u00e3o do ensaio cl\u00ednico DEFEAT-MB.<\/p>

Entre os integrantes da equipe, est\u00e3o:<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Nicholas A. Vitanza, MD<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

O Dr. Vitanza \u00e9 neuro-oncologista pedi\u00e1trico e pesquisador translacional \nno Seattle Children\u2019s. Ele dedica sua carreira ao cuidado de crian\u00e7as \ncom tumores fatais do c\u00e9rebro e da medula espinhal. Atua como \ndiretor cient\u00edfico do Programa de Pesquisa em Tumores Cerebrais \ndo hospital e lidera iniciativas em c\u00e9lulas CAR T. Seu trabalho integra \npesquisa laboratorial e desenvolvimento de novos ensaios cl\u00ednicos. Em \n2018, ele conduziu o in\u00edcio do primeiro ensaio cl\u00ednico com c\u00e9lulas CAR T \nadministradas diretamente no c\u00e9rebro de uma crian\u00e7a.<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Myron Evans, PhD<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

O Dr. Evans \u00e9 pesquisador principal do Ben Towne Center for Childhood \nCancer and Blood Disorders Research, no Seattle Children\u2019s. Seu \nlaborat\u00f3rio \u00e9 dedicado \u00e0 identifica\u00e7\u00e3o de novos alvos terap\u00eauticos para \ncrian\u00e7as com tumores cerebrais e da medula espinhal de alto risco.<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Os Drs. Vitanza e Evans est\u00e3o trabalhando na prepara\u00e7\u00e3o de ensaios cl\u00ednicos de \npr\u00f3xima gera\u00e7\u00e3o que combinam c\u00e9lulas CAR T com novos medicamentos. O Dr. \nVitanza est\u00e1 estudando c\u00e9lulas CAR T capazes de reconhecer m\u00faltiplas prote\u00ednas \nsimultaneamente, al\u00e9m de c\u00e9lulas CAR T com maior capacidade de migrar at\u00e9 os \ntumores.<\/p>

J\u00e1 o Dr. Evans busca identificar vulnerabilidades espec\u00edficas nos tumores de \ncada crian\u00e7a. Isso permitir\u00e1 o uso de medicamentos direcionados para \u201cpreparar\u201d \no c\u00e2ncer, tornando muito mais f\u00e1cil para as c\u00e9lulas CAR T encontr\u00e1-lo e destru\u00ed-lo. \nEmbora nenhum tratamento isolado seja suficiente, combina\u00e7\u00f5es terap\u00eauticas mais \ninteligentes e direcionadas podem finalmente mudar os desfechos.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u275d Sabemos que, quando o meduloblastoma recidiva, ele tende a \nreaparecer em v\u00e1rios locais. Estamos desenvolvendo c\u00e9lulas \nCAR T com maior capacidade de localizar o tumor onde quer \nque ele esteja, e isso nos oferece uma nova perspectiva sobre \ncomo tratar essas crian\u00e7as.\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u2014 Nicholas A. Vitanza, MD<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Jessica Foster, MD<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Dr. Foster is a principal investigator in the Center for Childhood\nCancer Research at CHOP. She is the hospital\u2019s central nervous\nsystem CAR T-cell lead and a pediatric neuro-oncologist.<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A Dra. Foster \u00e9 pesquisadora principal do Center for Childhood \nCancer Research do CHOP. Ela lidera as iniciativas de c\u00e9lulas CAR \nT para tumores do sistema nervoso central no hospital e atua como \nneuro-oncologista pedi\u00e1trica.<\/p>

\u201c\u00c9 como ajustar a dose de um medicamento\u201d, explica a Dra. Foster. \u201cPodemos controlar \no grau de atividade das c\u00e9lulas CAR T e a intensidade da inflama\u00e7\u00e3o que elas provocam em \ndeterminado momento.\u201d<\/strong><\/p>

A Dra. Foster, que tamb\u00e9m atua diretamente no atendimento aos pacientes, valoriza \na oportunidade de poder fazer a diferen\u00e7a com o apoio da MBI. \u201cAtualmente, quando \numa crian\u00e7a apresenta recidiva do meduloblastoma, precisamos ter uma conversa \nmuito dif\u00edcil com a fam\u00edlia\u201d, afirma. \u201cEspero que, com essas novas ferramentas baseadas \nno sistema imunol\u00f3gico, em breve possamos ter uma conversa completamente diferente \u2014 \numa conversa que inclua uma esperan\u00e7a real.\u201d<\/strong><\/p>

Os tr\u00eas novos integrantes da equipe da MBI trabalham em estreita colabora\u00e7\u00e3o com \na Dra. Haydar, compartilhando dados e contribuindo para aumentar as chances de \nsucesso do ensaio cl\u00ednico DEFEAT-MB. Cada um deles espera ajudar a liderar estudos \nadicionais com c\u00e9lulas CAR T nos pr\u00f3ximos dois anos. \u201cTemos potencial para realizar \nmais dois ou tr\u00eas estudos\u201d, afirma o Dr. Packer.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

O poder da conex\u00e3o: a MBI abre caminho para \num novo ensaio cl\u00ednico em Stanford<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Sheila Singh, MD, PhD, alcan\u00e7ou um dos primeiros grandes avan\u00e7os \nda MBI h\u00e1 4 anos. Seu laborat\u00f3rio na McMaster University, em \nOnt\u00e1rio, Canad\u00e1, desenvolveu as duas primeiras linhagens celulares \nhumanas reproduz\u00edveis de meduloblastoma do Grupo 4.<\/p>

Seu modelo celular, estabelecido com o apoio da MBI, contribuiu \npara a inclus\u00e3o de um bra\u00e7o dedicado ao meduloblastoma em um \nensaio cl\u00ednico com c\u00e9lulas CAR T na Stanford University, direcionado \u00e0 \nprote\u00edna GPC2. O futuro estudo DEFEAT-MB da MBI, no Children\u2019s National, \ncompartilha esse mesmo alvo terap\u00eautico, em conjunto com a prote\u00edna B7-H3.<\/p>

A Dra. Singh \u2014 que atualmente dirige a School of Cancer & Pharmaceutical Sciences \ndo King\u2019s College London e continua coordenando seu laborat\u00f3rio vinculado \u00e0 MBI \nno Canad\u00e1 \u2014 colaborou disponibilizando as c\u00e9lulas desenvolvidas com o apoio da \niniciativa. Os resultados foram impressionantes. Em seu modelo experimental, as \nc\u00e9lulas CAR T aumentaram a sobrevida contra o meduloblastoma em mais de 500%<\/p>

\u201cNunca vi nada parecido\u201d, afirma a Dra. Singh. Esses achados contribu\u00edram para o \nin\u00edcio do estudo em Stanford, liderado por Crystal Mackall, MD., Sabine Heitzeneder, \nMD, que participou anteriormente de reuni\u00f5es do cons\u00f3rcio da MBI, tamb\u00e9m integra \na lideran\u00e7a do ensaio cl\u00ednico<\/p>

A Dra. Singh celebra a forma como a MBI continua transformando o campo da \npesquisa em meduloblastoma. Quanto maior o n\u00famero de ensaios cl\u00ednicos, maiores \ns\u00e3o as chances de descobertas. \u201cEstamos investindo em m\u00faltiplas abordagens ao \nmesmo tempo\u201d<\/strong> afirma. \u201c\u00c9 exatamente disso que os pacientes precisam.\u201d<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Escaneie o QR code para ler \no artigo completo.
the full article.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A Dra. Singh reconheceu o apoio da MBI em seu artigo \u201cNovel models of group 4 medulloblastoma for \naccelerated preclinical discovery\u201d, publicado na revista Neuro-Oncology Pediatrics.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

OUTRAS ATUALIZA\u00c7\u00d5ES CIENT\u00cdFICAS<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Organoid Development\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

MBI labs at Children\u2019s National, Columbia University, the German Cancer Research Center and the University of California San Francisco continue to make strides toward developing a powerful medulloblastoma-specific research tool. Organoids, three-dimensional structures built from stem cells or patient samples, promise to recreate human tumors with greater accuracy than animal models.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Desenvolvimento de organoides\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Os laborat\u00f3rios da MBI no Children\u2019s National, na Columbia University, no German \nCancer Research Center e na University of California San Francisco continuam \navan\u00e7ando no desenvolvimento de uma poderosa ferramenta de pesquisa \nespec\u00edfica para o meduloblastoma. Os organoides, estruturas tridimensionais \nproduzidas a partir de c\u00e9lulas-tronco ou de amostras de tecido de pacientes, t\u00eam o \npotencial de reproduzir tumores humanos com maior acur\u00e1cia do que os modelos \nanimais.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Bi\u00f3psia l\u00edquida<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

O laborat\u00f3rio de bi\u00f3psia l\u00edquida do cons\u00f3rcio \u2014 liderado por Javad Nazarian, PhD, \nno Children\u2019s National \u2014 est\u00e1 aperfei\u00e7oando um teste que poder\u00e1 transformar \nsignificativamente tanto o cuidado quanto o tratamento dos pacientes. A bi\u00f3psia \nl\u00edquida permite que m\u00e9dicos detectem e monitorem a evolu\u00e7\u00e3o dos tumores \npor meio de uma simples amostra de fluido corporal. Essa abordagem reduz o \ndesconforto e os custos para as fam\u00edlias, ao mesmo tempo em que abre caminho \npara um acompanhamento mais preciso e interven\u00e7\u00f5es mais precoces. A chegada \nde Patrick \u201cP.J.\u201d Cimino, MD, PhD, um neuropatologista molecular de reconhecimento \ninternacional, ao Children\u2019s National em outubro de 2025 fortaleceu ainda mais \nesses esfor\u00e7os. Os Drs. Nazarian e Cimino pretendem validar o teste ainda este ano.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Dr. Vijay Ramaswamy lidera um laborat\u00f3rio \nda MBI no Hospital for Sick Children \n(SickKids), em Toronto, Canad\u00e1.<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Um acordo hist\u00f3rico no Brasil<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Em 5 de novembro de 2025, o Einstein Hospital Israelita e a MBI assinaram um acordo \nde coopera\u00e7\u00e3o cient\u00edfica com o objetivo de acelerar a pesquisa e o tratamento de \ntumores cerebrais pedi\u00e1tricos.<\/p>

Fundado em 1955, o Einstein Hospital Israelita destaca-se como refer\u00eancia mundial \nem assist\u00eancia \u00e0 sa\u00fade, pesquisa e responsabilidade social. Segundo a revista \nNewsweek, ocupa a 16\u00aa posi\u00e7\u00e3o entre os melhores hospitais do mundo, sendo a \ninstitui\u00e7\u00e3o mais bem classificada tanto do Hemisf\u00e9rio Sul quanto da Am\u00e9rica Latina<\/p>

A MBI colaborar\u00e1 com o hospital para promover o interc\u00e2mbio de conhecimento \ne apoiar futuros ensaios cl\u00ednicos. Ap\u00f3s a assinatura hist\u00f3rica do acordo, o Dr. Roger \nPacker ministrou a palestra intitulada<\/p>

Ap\u00f3s a assinatura hist\u00f3rica do acordo, o Dr. Roger \nPacker ministrou a palestra intitulada \u201cTransforming the Landscape of Medulloblastoma \nResearch and the MBI Model for Global Impact\u201d.<\/strong> A apresenta\u00e7\u00e3o destacou o papel \nfundamental que colabora\u00e7\u00f5es estrat\u00e9gicas como essa desempenham na busca \npor novas terapias<\/p>

Nos pr\u00f3ximos meses, a MBI anunciar\u00e1 novas atividades conjuntas com o Einstein \nHospital Israelita para ampliar a educa\u00e7\u00e3o e o conhecimento cient\u00edfico.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u275d Gra\u00e7as aos esfor\u00e7os da MBI, poderemos oferecer aos pacientes brasileiros \na oportunidade de acessar tratamentos experimentais por meio de ensaios \ncl\u00ednicos.\u201d<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

- Dr. Luiz Vicente Rizzo, Diretor de Pesquisa do Einstein Hospital Israelita<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Da esquerda para a direita: Dr. Luiz Vicente \nRizzo; Fernando Goldsztein; Dr. Sidney Klajner, \nPresidente do Einstein Hospital Israelita; \nDr. Roger Packer; Dr. Fernando Bacal, Vice\nPresidente do Einstein Hospital Israelita<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Fortalecendo a equipe da MBI<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

As pesquisas da MBI s\u00e3o financiadas integralmente por meio de filantropia \nprivada. Em maio, recebemos dois novos diretores executivos para ampliar nossa \ncapacidade de capta\u00e7\u00e3o de recursos. Ambos trazem ampla experi\u00eancia no setor \nsem fins lucrativos e j\u00e1 est\u00e3o ajudando a estender a esperan\u00e7a para milhares de \ncrian\u00e7as em todo o mundo.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

James R. Graham \n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Diretor Executivo \u2013 Estados Unidos<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

James R. Graham \u00e9 um estrategista s\u00eanior em filantropia, com mais \nde 25 anos de experi\u00eancia na capta\u00e7\u00e3o de recursos nas \u00e1reas de \nsa\u00fade, ensino superior, organiza\u00e7\u00f5es religiosas e institui\u00e7\u00f5es sem \nfins lucrativos. Ao longo de sua carreira, contribuiu para a obten\u00e7\u00e3o \nde mais de US$ 100 milh\u00f5es por meio de grandes doa\u00e7\u00f5es, \nparcerias, subs\u00eddios e campanhas de arrecada\u00e7\u00e3o.<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u275d Ao longo dos meus 25 anos de carreira, trabalhei com institui\u00e7\u00f5es extraordin\u00e1rias \u2014 \nmas nenhuma com uma lideran\u00e7a t\u00e3o apaixonada em um momento t\u00e3o importante. \nA MBI est\u00e1 alcan\u00e7ando avan\u00e7os extraordin\u00e1rios em pesquisa. Ao acelerar o processo \nde desenvolvimento de ensaios cl\u00ednicos, a iniciativa criou uma enorme esperan\u00e7a \npara as fam\u00edlias dessas crian\u00e7as t\u00e3o corajosas e estabeleceu um novo padr\u00e3o para \nparcerias em pesquisa, que servir\u00e1 de modelo em todo o mundo. Tenho orgulho de \nme juntar a uma organiza\u00e7\u00e3o que gera esse tipo de impacto.\u201d<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Natasha Alexander <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Executive Director Latin America\u200b<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Natasha Alexander brings more than 20 years of fundraising and\nmarketing leadership across global brands and nonprofits. She\npreviously championed the United Nations for Refugees fundraising\nprogram in Brazil. Her academic and professional background\nspans France, Germany, Brazil and the USA. She has supported\ngrowth initiatives in more than 30 countries.<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u275d Ao longo da minha trajet\u00f3ria em crescimento estrat\u00e9gico, sempre acreditei que \nmudan\u00e7as transformadoras acontecem quando a compaix\u00e3o \u00e9 acompanhada \npela a\u00e7\u00e3o. A MBI est\u00e1 redefinindo os horizontes da pesquisa por meio de uma \ncolabora\u00e7\u00e3o cient\u00edfica pioneira, acelerando descobertas e renovando a esperan\u00e7a \npara crian\u00e7as com meduloblastoma e suas fam\u00edlias. \u00c9 uma honra contribuir para \na expans\u00e3o dessa miss\u00e3o. Para cada crian\u00e7a que enfrenta o c\u00e2ncer, cada doador \ntorna-se parte da cura.<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

BRAVE KIDS \u2764\ufe0f<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Uma promessa para Kasey<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Por Alyssa e Joe Zachmann<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Nossa filha Kasey era uma crian\u00e7a criativa, art\u00edstica e \nincrivelmente compassiva. Estava sempre pensando \nnos outros, sempre muito atenta aos sentimentos e \u00e0s \nemo\u00e7\u00f5es das pessoas ao seu redor.<\/p>

Recebemos o diagn\u00f3stico de meduloblastoma em \n2021, e nosso mundo mudou instantaneamente. Ap\u00f3s o \ntratamento inicial no Children\u2019s National, mant\u00ednhamos a \nesperan\u00e7a.<\/p>

Mas, no in\u00edcio do 2\u00ba ano do ensino fundamental, em 2022, \ndescobrimos que o c\u00e2ncer havia retornado. Durante \ntodo o tratamento, mesmo nos momentos mais dif\u00edceis, \nKasey continuava pensando nos outros<\/p>

V\u00ea-la enfrentar dias t\u00e3o dif\u00edceis foi doloroso, mas \nguardamos in\u00fameras lembran\u00e7as preciosas dos \npequenos momentos vividos nos 3 anos que se seguiram \n\u00e0 recidiva. Muitas fam\u00edlias sequer t\u00eam essa oportunidade. \nKasey p\u00f4de ser daminha de honra ao lado de sua irm\u00e3 \nem um casamento. Guardaremos essas mem\u00f3rias para \nsempre. Kasey faleceu em agosto de 2025<\/p>

Desde o momento em que o c\u00e2ncer retornou, passamos \na concentrar nossos esfor\u00e7os na pesquisa cient\u00edfica. H\u00e1 \nmuita esperan\u00e7a nos estudos em andamento, mas uma \ncura ainda n\u00e3o foi encontrada.<\/p>

Prometemos continuar \nlutando at\u00e9 que ela seja encontrada, em homenagem \n\u00e0 Kasey. \u00c9 por isso que temos orgulho de apoiar a \nMedulloblastoma Initiative.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Uma nova voz na luta \ncontra o meduloblastoma<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Sabrina Castro tem uma conex\u00e3o \nprofunda com a miss\u00e3o da MBI. Ela \n\u00e9 m\u00e3e do Lucas, que enfrentou o \nmeduloblastoma corajosamente \npor 5 anos e faleceu em 2025. Desde \nent\u00e3o, Sabrina transformou seu luto em \nprop\u00f3sito.<\/p>

Sabrina vive em S\u00e3o Jos\u00e9 dos Campos, S\u00e3o \nPaulo, com seu marido, Andr\u00e9, e o filho mais \nnovo do casal, Matheus, de 7 anos.<\/p>

Desde \na partida de Lucas, tornou-se uma das mais \nimportantes mobilizadoras da comunidade da \nMBI. Ela mobiliza apoio em sua cidade, em todo \no Brasil e tamb\u00e9m internacionalmente. Inspira \noutras pessoas a se envolverem com a causa \ne representa uma fonte de for\u00e7a para fam\u00edlias \nafetadas pela doen\u00e7a<\/p>

Sua hist\u00f3ria nos lembra por que \nfazemos o que fazemos \u2014 e por \nquem continuamos lutando.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

MBI NA M\u00cdDIA<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Ao longo do \u00faltimo ano, alguns dos canais de comunica\u00e7\u00e3o mais \nimportantes do mundo compartilharam a hist\u00f3ria da MBI:<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Fox News Channel<\/strong>uma rede de not\u00edcias popular nos Estados Unidos, recebeu \nFernando Goldsztein para uma entrevista no programa Special Report, conduzida \npor Bret Baier, um dos \u00e2ncoras da emissora.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

MIT News<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

O MIT News divulgou que a MIT Sloan \nSchool of Management selecionou \na reportagem especial sobre a MBI \npublicada no ano anterior como \numa das 10 principais hist\u00f3rias de \nex-alunos de 2025.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

MS Now\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A MS Now (anteriormente conhecida como \nMSNBC), outra importante rede de not\u00edcias \ndos Estados Unidos, recebeu Fernando \nGoldsztein no programa Morning Joe para \numa discuss\u00e3o cient\u00edfica sobre o potencial \ndos ensaios cl\u00ednicos de imunoterapia da MBI.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

A visibilidade gerada por essas publica\u00e7\u00f5es reflete o esfor\u00e7o \ncoletivo da nossa comunidade para promover mudan\u00e7as na \nvida de todas as crian\u00e7as com meduloblastoma<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Revista People<\/strong> de publica\u00e7\u00e3o de alcance mundial reconhecida por suas reportagens \ncentradas em hist\u00f3rias humanas inspiradoras, destacou a miss\u00e3o da MBI em uma mat\u00e9ria \nespecial<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Fant\u00e1stico<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

O Fant\u00e1stico, um dos programas mais \ninfluentes e longevos da televis\u00e3o \nbrasileira, produziu uma reportagem \nespecial sobre a fam\u00edlia Goldsztein e a MBI \npara sua audi\u00eancia de aproximadamente \n33 milh\u00f5es de telespectadores.
approximately 33 million viewers.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Washington Post<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

O The Washington Post, um dos jornais \nmais importantes e respeitados dos Estados \nUnidos, publicou uma carta ao editor escrita \npor Fernando Goldsztein, na qual ele \ndefendeu o aumento dos investimentos em \npesquisas sobre c\u00e2ncer pedi\u00e1trico<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

SOBRE A MBI<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Uma hist\u00f3ria que precisa ser contada<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Em 2015, um menino chamado Frederico foi diagnosticado com meduloblastoma. \nEle tinha 9 anos de idade. Quatro anos depois, o tumor voltou. Seu pai, Fernando \nGoldsztein,recusou-se a aceitar que n\u00e3o existissem op\u00e7\u00f5es de tratamento para o \nfilho. Felizmente, eles conheceram o Dr. Roger Packer, um neurologista pedi\u00e1trico de \nrenome internacional.<\/p>

Juntos, o Dr. Packer e Fernando Goldsztein conceberam a ideia de criar \num cons\u00f3rcio de pesquisa totalmente dedicado \u00e0 busca da cura para o \nmeduloblastoma. Essa ideia tornou-se a base da MBI.<\/p>

O c\u00e2ncer \u00e9 complexo. A MBI tem orgulho de trabalhar em parceria com institui\u00e7\u00f5es \np\u00fablicas e privadas para enfrentar os desafios vividos pelos pacientes. Nosso foco \n\u00e9 a pesquisa cient\u00edfica, complementando os esfor\u00e7os realizados em todo o mundo.<\/p>

Nosso objetivo \u00e9 ambicioso e urgente. Nossa miss\u00e3o \u00e9 \nclara: captar recursos para viabilizar pesquisas \ncient\u00edficas de alto n\u00edvel que levem \u00e0 descoberta \nda cura para o meduloblastoma.<\/p>

Voc\u00ea pode nos ajudar a salvar milhares \nde crian\u00e7as. Fa\u00e7a uma doa\u00e7\u00e3o e \najude a divulgar essa causa.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Fernando and Frederico \nGoldsztein em Washington, D.C<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

O que \u00e9 a MBI?\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A Medulloblastoma Initiative (MBI) \u00e9 uma organiza\u00e7\u00e3o filantr\u00f3pica sem \nfins lucrativos dedicada ao financiamento de pesquisas cient\u00edficas sobre \no meduloblastoma, o tumor cerebral maligno mais comum na inf\u00e2ncia, \nque afeta aproximadamente 15 mil crian\u00e7as por ano<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Por que a pesquisa em \nmeduloblastoma precisa da MBI<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

O tratamento atualmente utilizado foi desenvolvido na d\u00e9cada de 1980 e \u00e9 \naltamente t\u00f3xico e ineficaz. Muitas crian\u00e7as ainda perdem a vida quando o \ntumor retorna ap\u00f3s o tratamento inicial.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Os recursos destinados \u00e0 pesquisa em c\u00e2ncer pedi\u00e1trico s\u00e3o extremamente \nlimitados, inclusive para o meduloblastoma, considerado uma doen\u00e7a rara.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Sem financiamento, nem mesmo as pesquisas mais b\u00e1sicas podem ser \nrealizadas, tornando extremamente dif\u00edcil propor e desenvolver novos \ntratamentos.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Como a MBI faz a diferen\u00e7a<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Os laborat\u00f3rios apoiados pela MBI trabalham de forma colaborativa e \ncompartilham dados antes de public\u00e1-los. Essa abordagem integrada \nacelera o desenvolvimento de protocolos terap\u00eauticos eficazes, com \no objetivo de disponibilizar novas terapias o mais r\u00e1pido poss\u00edvel.<\/p>

Em um marco extraordin\u00e1rio para nossa miss\u00e3o, crian\u00e7as j\u00e1 \nest\u00e3o recebendo os primeiros tratamentos experimentais \nem ensaios cl\u00ednicos desenvolvidos e financiados pela MBI.<\/p>

Em poucos anos, alcan\u00e7amos avan\u00e7os que normalmente \nlevariam uma d\u00e9cada ou mais para serem concretizados. \nNosso impacto representa o in\u00edcio de um novo cap\u00edtulo.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

MBI e Children\u2019s National: uma parceria \u00fanica<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A MBI capta doa\u00e7\u00f5es que s\u00e3o administradas \npelo Children\u2019s National, um dos 10 melhores \nhospitais pedi\u00e1tricos dos Estados Unidos, segundo \no ranking da U.S. News & World Report.<\/strong>Sua \ncontribui\u00e7\u00e3o filantr\u00f3pica apoia o trabalho de \num cons\u00f3rcio formado por 16 laborat\u00f3rios \nde excel\u00eancia internacional localizados nos \nEstados Unidos, Canad\u00e1 e Alemanha.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

PARCEIROS DO CONS\u00d3RCIO<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

O modelo da MBI<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A MBI utiliza um modelo estruturado e confi\u00e1vel para transformar uma causa \nrelacionada \u00e0 sa\u00fade em uma iniciativa de impacto efetivo. Esse modelo conecta \numa hist\u00f3ria inspiradora, um especialista cient\u00edfico renomado, uma institui\u00e7\u00e3o de \nrefer\u00eancia e um cons\u00f3rcio de pesquisa orientado para resultados. Essa combina\u00e7\u00e3o \ngarante uma estrat\u00e9gia clara, credibilidade e impacto mensur\u00e1vel.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The\nMedulloblastoma \nInitiative<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Scientific Consortium<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Children\u2019s national Hospital<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u275d O modelo da MBI para financiar a busca por curas para doen\u00e7as \nraras \u00e9 replic\u00e1vel e tem potencial para transformar a forma \ntradicional como a pesquisa em sa\u00fade \u00e9 financiada e conduzida, \nreduzindo drasticamente o tempo necess\u00e1rio para alcan\u00e7ar \nresultados.\u201d\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

- Artigo da MIT Sloan School of Management, 21 de janeiro de 2025<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Voc\u00ea ainda usa \nessas tecnologias?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

D\u00e9cada de 1980: a d\u00e9cada em que o protocolo de tratamento para \nmeduloblastoma foi estabelecido. O mesmo protocolo que continua sendo \nutilizado por m\u00e9dicos em todo o mundo. Al\u00e9m de n\u00e3o curar at\u00e9 um em cada \ntr\u00eas pacientes, os tratamentos atualmente dispon\u00edveis podem causar efeitos \ncolaterais graves e permanentes nos sobreviventes.<\/p>

A MBI acredita que a pesquisa pode mudar essa triste realidade. Por isso, \ntrabalhamos para conectar doadores privados aos principais especialistas \nda \u00e1rea. Voc\u00ea tamb\u00e9m pode fazer parte dessa miss\u00e3o: ajude a divulgar essa \ncausa e fa\u00e7a uma doa\u00e7\u00e3o para levar esperan\u00e7a e novas possibilidades de \ncura a crian\u00e7as de todo o mundo.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

Contribua j\u00e1!<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

www.mbiiniative.org<\/a><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Escaneie para doar<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Relat\u00f3rio #10<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

EQUIPE DA MBI\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Fernando Goldsztein
<\/strong>Fundador<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Mauro Dorfman
<\/strong>Coordenador estrat\u00e9gico<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Martina Fischer
<\/strong>Filantropia e relacionamento<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Alessandra Chang
<\/strong>Gerente de projetos
<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Iago Paz
<\/strong>Design e desenvolvimento
<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

James Graham
<\/strong>Diretor Executivo \u2013 Estados Unidos<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Natasha Alexander
<\/strong>Diretora Executiva \u2013 Am\u00e9rica Latina<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Andr\u00e9 Fay
<\/strong>Consultor volunt\u00e1rio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Sabrina Castro
<\/strong>Consultor volunt\u00e1rio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Claudia Buchweitz
<\/strong>Copy Editing<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Children\u2019s National
\nHospital Foundation<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Kerri Yoder Hubbard
<\/strong>Presidente Associada, \nGrandes Doa\u00e7\u00f5es e
Doa\u00e7\u00f5es Principais<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Andrew Miller
<\/strong>Diretor de Desenvolvimento,
Neuroci\u00eancias e Medicina Comportamental<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Emma Younger
<\/strong>Assistente de Desenvolvimento,
Neuroci\u00eancias e Medicina Comportamental<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

\u275d Whoever saves one life\n saves the world entire.\u275e<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u2014 Talmud<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\n\t\n<\/svg>\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u00c9 poss\u00edvel dar ESPERAN\u00c7A<\/strong> a crian\u00e7as
\ncom tumores cerebrais letais?
A MBI diz SIM<\/strong>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Apoie a MBI hoje<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

The Medulloblastoma Initiative Impact Report June 2026 Lynne El Ghorayeb PharmD (left), and Dalia Haydar, PharmD, PhD, who leads an immunotherapy lab at Children\u2019s National Hospital, prepare to launch a new clinical trial with support from the Medulloblastoma Initiative FROM NEW COLLABORATIONS TO GROUNDBREAKING TRIALS \u275d CAR T-cell technologies represent a tremendous opportunity to improve […]<\/p>\n","protected":false},"author":11,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-8761","page","type-page","status-publish","hentry"],"yoast_head":"\nImpact Report | June 2026 - The Medulloblastoma Initiative<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mbinitiative.org\/pt\/impact-report-june-2026\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Impact Report | June 2026 - The Medulloblastoma Initiative\" \/>\n<meta property=\"og:description\" content=\"The Medulloblastoma Initiative Impact Report June 2026 Lynne El Ghorayeb PharmD (left), and Dalia Haydar, PharmD, PhD, who leads an immunotherapy lab at Children\u2019s National Hospital, prepare to launch a new clinical trial with support from the Medulloblastoma Initiative FROM NEW COLLABORATIONS TO GROUNDBREAKING TRIALS \u275d CAR T-cell technologies represent a tremendous opportunity to improve […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mbinitiative.org\/pt\/impact-report-june-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"The Medulloblastoma Initiative\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/themedulloblastomainitiative\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-01T18:27:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mbinitiative.org\/wp-content\/uploads\/2023\/11\/logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"591\" \/>\n\t<meta property=\"og:image:height\" content=\"262\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data1\" content=\"31 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/mbinitiative.org\\\/impact-report-june-2026\\\/\",\"url\":\"https:\\\/\\\/mbinitiative.org\\\/impact-report-june-2026\\\/\",\"name\":\"Impact Report | June 2026 - The Medulloblastoma Initiative\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mbinitiative.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/mbinitiative.org\\\/impact-report-june-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/mbinitiative.org\\\/impact-report-june-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mbinitiative.org\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/image-26-1.svg\",\"datePublished\":\"2026-06-18T19:47:20+00:00\",\"dateModified\":\"2026-07-01T18:27:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/mbinitiative.org\\\/impact-report-june-2026\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/mbinitiative.org\\\/impact-report-june-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/mbinitiative.org\\\/impact-report-june-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mbinitiative.org\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/image-26-1.svg\",\"contentUrl\":\"https:\\\/\\\/mbinitiative.org\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/image-26-1.svg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/mbinitiative.org\\\/impact-report-june-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/mbinitiative.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Impact Report | June 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/mbinitiative.org\\\/#website\",\"url\":\"https:\\\/\\\/mbinitiative.org\\\/\",\"name\":\"The Medulloblastoma Initiative\",\"description\":\"Cura do Meduloblastoma Infantil\",\"publisher\":{\"@id\":\"https:\\\/\\\/mbinitiative.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/mbinitiative.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/mbinitiative.org\\\/#organization\",\"name\":\"The Medulloblastoma Initiative\",\"url\":\"https:\\\/\\\/mbinitiative.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/mbinitiative.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/mbinitiative.org\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/LOGO-MBI.png\",\"contentUrl\":\"https:\\\/\\\/mbinitiative.org\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/LOGO-MBI.png\",\"width\":354,\"height\":168,\"caption\":\"The Medulloblastoma Initiative\"},\"image\":{\"@id\":\"https:\\\/\\\/mbinitiative.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/themedulloblastomainitiative\",\"https:\\\/\\\/www.instagram.com\\\/medulloblastomainitiative\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/medulloblastomainitiative\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@mbinitiative\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Impact Report | June 2026 - The Medulloblastoma Initiative","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mbinitiative.org\/pt\/impact-report-june-2026\/","og_locale":"pt_BR","og_type":"article","og_title":"Impact Report | June 2026 - The Medulloblastoma Initiative","og_description":"The Medulloblastoma Initiative Impact Report June 2026 Lynne El Ghorayeb PharmD (left), and Dalia Haydar, PharmD, PhD, who leads an immunotherapy lab at Children\u2019s National Hospital, prepare to launch a new clinical trial with support from the Medulloblastoma Initiative FROM NEW COLLABORATIONS TO GROUNDBREAKING TRIALS \u275d CAR T-cell technologies represent a tremendous opportunity to improve […]","og_url":"https:\/\/mbinitiative.org\/pt\/impact-report-june-2026\/","og_site_name":"The Medulloblastoma Initiative","article_publisher":"https:\/\/www.facebook.com\/themedulloblastomainitiative","article_modified_time":"2026-07-01T18:27:31+00:00","og_image":[{"width":591,"height":262,"url":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2023\/11\/logo.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. tempo de leitura":"31 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/mbinitiative.org\/impact-report-june-2026\/","url":"https:\/\/mbinitiative.org\/impact-report-june-2026\/","name":"Impact Report | June 2026 - The Medulloblastoma Initiative","isPartOf":{"@id":"https:\/\/mbinitiative.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mbinitiative.org\/impact-report-june-2026\/#primaryimage"},"image":{"@id":"https:\/\/mbinitiative.org\/impact-report-june-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2025\/02\/image-26-1.svg","datePublished":"2026-06-18T19:47:20+00:00","dateModified":"2026-07-01T18:27:31+00:00","breadcrumb":{"@id":"https:\/\/mbinitiative.org\/impact-report-june-2026\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mbinitiative.org\/impact-report-june-2026\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/mbinitiative.org\/impact-report-june-2026\/#primaryimage","url":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2025\/02\/image-26-1.svg","contentUrl":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2025\/02\/image-26-1.svg"},{"@type":"BreadcrumbList","@id":"https:\/\/mbinitiative.org\/impact-report-june-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/mbinitiative.org\/"},{"@type":"ListItem","position":2,"name":"Impact Report | June 2026"}]},{"@type":"WebSite","@id":"https:\/\/mbinitiative.org\/#website","url":"https:\/\/mbinitiative.org\/","name":"(The Medulloblastoma Initiative)","description":"Cura do Meduloblastoma Infantil","publisher":{"@id":"https:\/\/mbinitiative.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mbinitiative.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/mbinitiative.org\/#organization","name":"(The Medulloblastoma Initiative)","url":"https:\/\/mbinitiative.org\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/mbinitiative.org\/#\/schema\/logo\/image\/","url":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2023\/10\/LOGO-MBI.png","contentUrl":"https:\/\/mbinitiative.org\/wp-content\/uploads\/2023\/10\/LOGO-MBI.png","width":354,"height":168,"caption":"The Medulloblastoma Initiative"},"image":{"@id":"https:\/\/mbinitiative.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/themedulloblastomainitiative","https:\/\/www.instagram.com\/medulloblastomainitiative\/","https:\/\/www.linkedin.com\/company\/medulloblastomainitiative\/","https:\/\/www.youtube.com\/@mbinitiative"]}]}},"_links":{"self":[{"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/pages\/8761","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/comments?post=8761"}],"version-history":[{"count":862,"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/pages\/8761\/revisions"}],"predecessor-version":[{"id":9877,"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/pages\/8761\/revisions\/9877"}],"wp:attachment":[{"href":"https:\/\/mbinitiative.org\/pt\/wp-json\/wp\/v2\/media?parent=8761"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}